ABSTRACT
INTRODUCTION
Evidence supporting many facets of the observed biological functions of bone sialoprotein (BSP) and osteopontin (OPN) has been accumulating, with a wide range of implications in both mineralizing and non-mineralizing tissues. BSP and OPN are the major non-collagenous extracellular matrix (ECM) phosphoproteins of calcified tissues such as bone and cartilage. Their intimate relationship with biomineralization suggested that they play key roles during the development and maintenance of these tissues (1) (2) (3) (4) (5) (6) (7) (8) . Studies in vitro using BSP and OPN indicated that while BSP induces Ca-P apatite formation (4-6;9), OPN lacks this property or is inhibitory (3;4;10) . The biological functions of BSP and OPN are not limited to mineral deposition but impact cellular behavior such as cell motility, cell adhesion and bone resorption (10) (11) (12) (13) (14) (15) (16) . Despite extensive studies however, the precise roles of these phosphoproteins remain to be clearly defined. While some studies in vitro indicated that BSP promotes bone resorption and hence participates in bone degradation (17) , other studies such as those using glucocorticoids, which increased expression of this protein, suggested its involvement in the anabolic phase of bone remodeling (18) . In this laboratory in vivo implants of BSP-collagen composites in the calvarial critical defect bone repair model (19) and during reparative dentinogenesis (7;8;20-22) highlighted the impact of BSP during biomineralization and new bone/dentin formation.
As interest continues and evidence accumulates with regard to the general biological functions of bone phosphoproteins, in particular the covalently-bound phosphate groups, the biochemical factors or processes that can affect the state of phosphorylation of these proteins become significant. Hence, the protein kinases that are involved in the phosphorylation of BSP/OPN prior to secretion into the extracellular matrix (ECM) become important regulators of ECM phosphoprotein functions. Previous studies from this laboratory defined that the microsomal casein kinase type II (mCKII)/casein kinase II were the predominant enzymes involved during the phosphorylation of bone ECM phosphoproteins, OPN and BSP (23) (24) (25) (26) . Also, the use of a panel of purified protein kinases in in vitro phosphorylation of purified bovine bone OPN and BSP demonstrated that the degree of in vivo naturally occurring phosphorylation of bovine BSP and OPN were ~65% and ~85%, respectively. Not all of the molecules are phosphorylated on each of the potential phosphorylation sites within a given population of molecules isolated from bone of a particular age. Such heterogeneity in the phosphorylation can be attained by changes in factors such as the rate of phosphoprotein synthesis, the mCKII activity, the available ATP concentrations (within the intracellular compartment where phosphorylation takes place), and some degree of dephosphorylation during their residence in the ECM. The precise sites of phosphorylation on chicken bone OPN clearly defined that the extent of phosphorylation on each site varied between 30-100%, with an average of ~60% total phosphorylation (27) . There were 10 phosphorylated sites identified, but the actual quantitative analysis showed 6.3 mols of phosphoaminoacids/mol of chicken OPN. The phosphorylated peptide regions were predominantly recognition sequences for CKII (27) , confirming our in vitro studies. Further studies which utilized the in vivo repair of calvarial bone defects induced to heal by implants of demineralized bone matrix highlighted the intimate interrelationship between accumulation and rate of accumulation of Ca-P, OPN, BSP and mCKII activity as a function of bone development (28) . More recently direct evidence was provided for the first time in support of the concept of a "natural variation" in the extent of phosphorylation of ECM phosphoproteins during mineralized tissue formation. The extent of phosphorylation of OPN and BSP in the two anatomically distinct in vivo sites (bony and soft tissue) was substantially different (varied between ~1 to ~14 mols of P-Ser/mol of OPN or BSP), and varied as a function of time within both implant sites (29) . Furthermore, there was a direct and linear relationship between the "rate" of Ca-P deposition and the ratio of P-Ser-BSP/P-Ser-OPN for calvarial implants, which clearly demonstrated hidden and important facets of the factors that control mineral deposition, and the intimate coupling of the state of phosphorylation of BSP and OPN in this process.
Indeed, the covalently-bound phosphates of BSP and OPN have been also shown to effect osteoclast cell attachment properties (15;30) . More recent conflicting studies have utilized different forms of OPN and BSP which suggested that while phosphorylation was not important for cell attachment, it was however, necessary for in vitro osteoclast resorption pit formation in dead bone slices (31) . The differences in the results between these studies, (15;30) vs. (31) , were suggested to be due to the differences in the protein samples and state of phosphorylation. There is no doubt that such conflicting results will probably continue to arise since these proteins are highly phosphorylated/ glycosylated and as noted above these moieties are subject to inherent "natural variation" (29) .
Phosphorylation does not take place to the same extent on each of the potential sites, which leads to heterogeneity within a given population of the protein isolated from a natural source. In vitro phosphorylation can also produce proteins with heterogeneous phosphorylation states or fully phosphorylated forms, but in either case these may not represent precisely the naturally occurring forms.
The phosphorylation sites and regions of chicken bone OPN (27) and bovine milk OPN (32) and the glycosylation sites of human BSP (33;34) have been reported. However, similar details are not available for BSP phosphorylation sites. In the present study a combination of state-of-the-art experimental approaches have been utilized to define for the first time the complete topographical distribution of both the in vitro and in vivo phosphorylation sites of bovine bone BSP. These included:
(i) phosphorylation of native and deglycosylated BSP by CKII, tryptic peptide mapping followed by solid-phase N-terminal peptide sequence analyses to define in vitro phosphorylation sites; (ii) use of a novel synthesized radiolabeled thiol agent ( 14 C-CM-DTT) to derivatize phosphoserine tryptic peptides of BSP followed by normal N-terminal peptide sequence analysis to define in vivo phosphorylation sites; and (iii) use of MALDI-TOF-MS to rapidly profile BSP proteolytic peptides. and fractions of 0.5 ml were collected. Aliquots from each fraction were counted for 32 P radioactivity and the radioactive fractions were then separately pooled for each peak, freeze dried, and rechromatographed. Each purified 32 P-labeled peptide was then sequenced by automated solid-phase amino acid sequencing both to define the sequence and to identify the precise site(s) of phosphorylation, as described previously (27) . (28;29) were pooled and freeze dried. The sample was then phosphorylated using CKII and [ 32 P]ATP, trypsin digested and peptides separated by RP-HPLC, as described above. The 32 P-labeled peptides were subjected to solid-phase N-terminal sequence analyses to define simultaneously the peptide sequence identity and the location of the phosphorylated residue(s), as described previously (27) . To evaluate quantitatively, analysis were performed to calculate accurately the degree of absolute phosphorylation in vivo and in vitro at each site and relative to the others within the whole molecule. Since there is an unknown amount of phosphate loss from the P-Ser residues under Edman degradation cycles, it is not possible to quantify P-Ser content from release of 32 P alone at that cycle. One way that this was overcome was to calculate the pmols of 32 PSer released (from 32 P counts and the specific activity of the 32 P-ATP) plus the pmols of dehydroalanine observed at that cycle. This approximated more closely the actual original P-Ser content of the peptide, since generation of the dehydroalanine from the P-Ser is cumulative during Edman degradation. (27) . To define the peptide sequence and the location of the phosphoserine/phosphothreonine containing residues, one third of the ATZ products of each Edman degradation step were converted to phenylthiohydantoin-derivatives and analyzed by on line HPLC (model 120A, Applied Biosystems), and two thirds were collected as ATZ-derivatives for 14 Ccounting as described recently (27, 36) . Unlike the analysis and quantification of the in vitro 32 Plabeled peptides by solid-phase sequencing above, the quantification of the P-Ser content during spotted on to a sample target (stainless steel sample plate), allowed to dry and loaded into the mass spectrometer for analysis.
MATERIALS AND METHODS

In
RESULTS
Complete in vitro phosphorylation sites of purified bovine bone BSP using 32 P-ATP and CKII- Figure 1A shows tryptic peptide map of native BSP phosphorylated using 32 P-ATP and casein kinase II (CKII). The BSP used in this experiment was native with both glycosylation and phosphorylation intact. Under these circumstances 32 P-labeling occurs at residual phosphorylation sites with recognition sequences for CKII. A number of 32 P-labeled peptides were observed within the RP-HPLC profile using a C-18 column. Several of the peptides were subjected to rechromatography using RP-HPLC for clarification of the sequences, Fig. 1A inset. It is worth noting that the absorbance profile of each peak is heightened with the descending limb never declining to baseline, which is obvious both in Fig. 1A and its inset. This phenomenon is a prominent occurrence in the analysis of phosphoproteins with high level of glycosylation, as is the case with BSP in the present work and that previously reported for OPN (27) . In order both to simplify the tryptic peptide map and to remove the uncertainty of possible 32 P-incorporation on glycosylated side chains, native BSP was first deglycosylated by a combination of glycosidases followed by phosphorylation and peptide mapping, Fig. 1B . The peptide map of the deglycosylated BSP clearly revealed simplification and sharpening of the absorbance peaks, including baseline approximation of the peak limbs, observed for both Fig. 1B and its inset. Interestingly, however, neither the number of radioactive peaks nor their relative positions and intensities within each profile showed any significant change. This suggested that the peptide sequences and sites for phosphorylation and glycosylation do not overlap, and was supported by the quantitative data relating mols of 32 P-incorporation/mol of native and deglycosylated BSP (~2.5 mol of phosphate/mol of protein in both cases). Sequence analysis of the phosphorylated peptide regions and sites provided direct evidence consistent with this. Each of the radiolabeled fractions from both Figs 1A and 1B were N-terminal sequenced using the solid-phase automated sequencing approach. Three peptides were identified as in vitro 32 P-labeled peptides: residues 12-22 (LEDS P EENGVFK), 42-122 (FAVQSSSDSS P EENGNG DS P S P EEEEEE-EETSNEEGNNGGNED S P DENEDEES P EA----), and 135-216 (EDES P DEEEEEEEE----) with specific phosphorylated residues denoted by superscript P. The length of the tryptic peptide with residues 42-122 was too long for the positions of all of the potential phosphorylated serines beyond ~12-15 residues to be defined clearly. Hence, a portion of this peptide was N-terminal sequenced up to 12 residues to identify the phosphorylated residues within this section. The remaining peptide was further proteolytically digested by Asp-N endopeptidase and the shorter radiolabeled peptides isolated and sequenced. Overall, seven phosphorylated sites were defined within the three peptides. As expected, all of the phosphorylated peptides contain recognition sequences for CKII (SEE, SXE, ESDE etc), i.e. the phosphorylated serine residues are flanked with acidic amino acids (E or D). Figure 4 summarizes the topographical distribution of phosphorylation sites within the primary amino-acid sequence of bovine BSP and Table 1 
(FAVQS P SSDSS P EENGNGDS P S P EEEEEEEETSNEEGNNG GNED S P DENEDEES P EA----), 135-216 (EDES P D (-----EIYES P ENGDPR)
, and 272-285 (GYDS P YDGQDYYSHQ), with the specific phosphorylated residues denoted by superscript P. The peptides with residues 42-122 and 235-264 were subjected to additional proteolytic digestion with Asp-N endopeptidase in order to define the precise location of the phosphorylated residue(s). The [ 14 C]CM-DTT derivatized peptides were sequenced under normal Edman degradation conditions using Biobrene treated glass filters. Figure 2 shows sequence data for the first 12 cycles of the peptide starting with residue Phe-42 obtained under such conditions. Overall, almost all of the peptides that were found to be phosphorylated in vitro by CKII were also found to be in vivo phosphorylated. The exceptions were two additional peptides with residues 235-264 (-----EIYES P ENGDPR) and 272-285 (GYDS P YDGQDYYSHQ), and an additional phosphorylation site at position 46 of the peptide with residues 42-122 were identified. These data indicate that most of the phosphorylation sites of native BSP were partially phosphorylated in vivo and two sites on the Nterminal domain were either fully phosphorylated or somewhat not recognized or not accessible by CKII. 
Identification of in vivo phosphorylation sites by direct MALDI-TOF-MS analysis -
DISCUSSION
The present study utilized a combination of multiple state-of-the-art approaches, techniques and reagents to define the complete topographical distribution of both in vitro and in vivo phosphorylation sites and regions of bovine bone BSP. These sites included the complete in vitro phosphorylation regions and specific sites (indicated by superscript P) of peptides with residues 12-22 (LES P DEENGVFK), residues 42-62 (FAV QSSSDSS P EENGN-GDS P S P EE), residues 80-91 (EDS P DENEDEES P E), and residues 135-141 (EDES P DEE). While these data in their own right are significant, there is no doubt that they may represent only part of the overall possible phosphorylation state/sites of native BSP. This is because in vitro phosphorylation was carried out using a single enzyme (CKII), and this process relies on the presence of partially phosphorylated peptides within the native population of BSP molecules. Hence, identification of the complete in vivo phosphorylation sites and regions of native bovine BSP was pursued. To accomplish this task, novel reagents developed in this laboratory were used. Thiol agents such as DTT and [ 3 H]CM-DTT, used as tools to explore the general phenomenon of phosphorylation in conjunction with instrumentation to perform N-terminal sequencing and MALDI-TOF-MS, have been very recently described in detail from this laboratory (35;36) . These approaches led to the identification of in vivo phosphorylation sites, which included all of the phosphopeptides identified by in vitro CKII phosphorylation of BSP (peptides described above).
However, three additional phosphopeptides were identified by 14 C-radiolabeling: residues starting with Glu-135 (EDES P DEEEEEE----), Asp-240 (DNGYEIYES P ENGDPR) and Gly-272 (GYDS P YDGQ----). Furthermore, the use of native BSP proteolytic peptides and MALDI-TOF-MS provided confirmation of several identified peptide regions by 32 P-labeling (in vitro) and [ 14 C]CM-DTT derivatization (in vivo), but in addition the peptide with residues 125-130 (AGAT P GK) was identified, which was not defined by either of the above approaches. This phosphopeptide, unlike the others, does not have a recognition sequence for phosphorylation by CKII. Instead, the amino-acids flanking the phosphothreonine constitute a recognition site (XT/SXK) for phosphorylation by PKC, and indeed is the reason why we did not define this site by using CKII in our in vitro studies. Importantly, however, our previous in vitro quantitative studies using a panel of protein kinases, did highlight the presence of a PKC phosphorylation site in bovine bone BSP (26) , whose location now is defined herein. Also, this is the only phosphorylated BSP peptide where the site of phosphorylation is not a serine residue but rather threonine, and was not identified by the thiol agent approach because P-threonine residues undergo base-catalyzed elimination much slower than the P-serine residues. The identification of in vitro phosphorylation sites (using 32 P-ATP and CKII) of native bovine BSP were carried out with samples of native BSP with and without glycosylation. Such an approach was of importance for two reasons: (i) to simplify the tryptic peptide maps because presence of glycosylation leads to peak broading, and (ii) to eliminate the possibility of 32 P-incorparation on the glycosyl site chains. Figure   1 shows the impact of deglycosylation on the peptide profile with clear peak sharpening. Similarly but for different reason, the identification of in vivo phosphorylation sites by [ 14 C]CM-DTT derivatization were carried out using deglycosylated native BSP. This was an essential step since under base-catalyzed conditions the O-glycosyl sites can undergo elimination reaction similar to PSer/P-Thr residues that will generate unsaturated double bond with which [ 14 C]CM-DTT will react.
Overall, the present work provides the most extensive and detailed study to date of the precise location of 11 in vivo and 7 in vitro phosphorylation sites. Figure 4 summarizes the overall sites of phosphorylation of BSP both in vivo and in vitro as defined in the present work and the sites of glycosylation for human BSP, which have been recently reported (33) . Interestingly, the glycosylation and phosphorylation sites do not overlap, and the glycosylation sites are concentrated in the midportion of the protein, somewhat sandwiched in between the N-terminal phosphorylation sites and those of the C-terminal phosphorylation sites. Clearly, these structural features raise a series of possible biologic functions for such posttranslational modifications and how they may couple to provide specific functional consequence. The role of BSP in biomineralization has been implicated by its temporal deposition into the ECM during development of the mineralizing tissues (1; 38-40), its high affinity for hydroxyapatite (41) and its action as a de novo nucleator of hydroxyapatite crystals in vitro (4). The poly-Glu regions have been suggested to be involved in hydroxyapatite binding and nucleation of Ca-P crystals (5) . Similarly, its glycosylation has been also shown to influence hydroxyapatite binding (33) . Prior to these developments, the participation of the covalently-bound phosphates on ECM phosphoprotein-collagen complexes in Ca-P deposition was described (42) . The complete topographical distribution and location of the phosphorylated regions/sites of BSP defined herein presents a plausible synergistic activity between these moieties both in hydroxyapatite binding and Ca-P crystal nucleation. Previous work from this laboratory established the quantitative extent of both in vitro and in vivo phosphorylation of BSP using a panel of purified protein kinases and 32 P-ATP (26) . In that study the total degree of phosphorylation was defined and the global domains that contained such modifications, including the predominant protein kinase (CKII) that participates during phosphorylation of BSP. However, the precise locations of the phosphorylation sites and peptide regions were not identified. The location of one phosphoserine in the N-terminal half of BSP, residues 12-22 (LESDEENGVFK), was identified by in vitro 32 P-labeling with CKII and solid-phase Nterminal sequence analysis. A second phosphopeptide was identified consisting of residues (FAVQSSSDSSEENGNGDSSEEE--) containing up to five phosphorylated residues, but the precise locations of these sites within the sequence were not defined at that time (25) . The peptide with residues 12-22 was latter identified to be also phosphorylated in vivo (34, 36) . In addition, a MALDI-TOF-MS approach was used to predict, based on mass difference, that a peptide with residues 130-203 in human bone BSP contained 0-4 phosphorylated P-Ser or P-Thr residues (34) . However, because this peptide contains fourteen potential phosphorylation sites (seven Ser and seven Thr residues) on which the four phosphates may be residing, it was not possible to define the precise location of these phosphate groups. Thus, only one phosphorylation site was defined unequivocally from previous studies to date (25, 34, 36) , compared with eleven in vivo and seven in vitro sites in the present work.
To gain further insights into the biological implications of the phosphorylation state, we have performed extensive quantitative analysis on the extent of phosphorylation at each site both in vivo and in vitro. These data demonstrate the variation in the state of phosphorylation at each site ( Table 1 . Fractions of 0.5 ml were collected and aliquots counted for 32 P radioactivity (dashed line). Inset: rechromatography of fraction 3, using same HPLC conditions as above. B: 100 µg of deglycosylated BSP was 32 P-labeled using 32 P-ATP and CKII followed by trypsin digestion. The peptides were separated by reverse-phase HPLC on a Vydac C-18 column as described for (A) except the linear gradient was performed over a 60 min, at a flow rate 1.0 ml/min and 1.0 ml fractions were collected. Solid line is the absorbance 219 nm and dashed line 32 P radioactivity.
Inset: rechromatography of fraction 3. Under the same HPLC conditions. C: 100 µg of deglycosylated BSP was first trypsin digested and the phosphoserine peptides 14 C-labeled using 5 mM [ 14 C]CM-DTT in 0.33 M NaOH at 50 0 C for 1 hr. The peptides were separated by reverse-phase HPLC on a Vydac C-18 column as described for (B). During N-terminal sequencing one third of Edman degradation products was analyzed as PTH-amino acid and two thirds were collected and counted for 14 C radioactivity, 2020 dpm and 780 dpm were recovered at cycles 5 and 10 respectively. Initial yield, I = 250 pmol; repetitive yield, R = 90%; =, log 10 (pmol of amino acid) at each cycle. • = glycosylation sites recently reported (33) . Note superscript asterisks (*) following the amino acid denotes phosphorylated residues.
